Form 4: LifeStance Chief People Officer Sells 50,000 Shares

LifeStance Health Group's Chief People Officer, Ann Varanakis, sold 50,000 shares of common stock for approximately $345,000.

Summary

• Ann Varanakis, Chief People Officer of LifeStance Health Group, Inc. (LFST), disposed of 50,000 shares of common stock.
• The transaction occurred on December 17, 2025, at a weighted average price of $6.90 per share.
• The total value of the shares sold was approximately $345,000.
• Following this transaction, Ann Varanakis beneficially owns 315,610 shares of LifeStance Health Group common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was pre-arranged.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider sale, although mitigated by the fact it was executed under a Rule 10b5-1 plan, suggesting a pre-scheduled transaction rather than an immediate reaction to new information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it may suggest a lack of confidence in the company's future prospects by a key executive.

Risks

• Significant insider selling, particularly by multiple executives, could signal underlying issues or a belief that the stock is overvalued, potentially leading to negative investor sentiment and downward pressure on the share price.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider sales are a routine part of executive compensation and personal financial planning, especially when executed under a Rule 10b5-1 plan. In the healthcare services industry, executive stock transactions are closely watched for signals about company performance and valuation, though a single transaction under a pre-planned schedule may not indicate a significant shift in industry trends.

Comparison to Industry Standards

• The sale of shares by a Chief People Officer is a common occurrence across industries, often for personal financial planning or diversification.
• The use of a Rule 10b5-1 plan is a standard practice for insiders to sell shares without being accused of trading on material non-public information, providing a defense against insider trading allegations. This practice is widely adopted by executives in publicly traded companies, including those in the healthcare sector, to manage their equity holdings systematically.

Related Party Transactions

• The sale of 50,000 shares of common stock by Ann Varanakis, a Chief People Officer, constitutes a related party transaction as it involves a key executive of the company.

Stakeholder Impact

• Shareholders may view this insider sale with caution, potentially interpreting it as a signal about the company's future prospects or valuation, which could influence their investment decisions.
• Employees might observe executive stock transactions as an indicator of management's confidence in the company, though a Rule 10b5-1 sale is less likely to cause alarm than an unscheduled sale.

Key Dates

Recommendation

While an insider sale can be a negative signal, the transaction was executed under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not necessarily indicative of new negative information. Without additional context on the company's fundamentals or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future developments rather than making an immediate buy or sell decision based solely on this Form 4.

Keywords

LifeStance Health Group, LFST, Insider Sale, Form 4, Ann Varanakis, Chief People Officer, Stock Transaction, Rule 10b5-1